A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High‐dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2‐positive Breast Cancer. This evidence concerns the gene ERBB2 and breast cancer.